Gérald Simonneau1, Andrea M D'Armini2, Hossein-Ardeschir Ghofrani3, Friedrich Grimminger4, Pavel Jansa5, Nick H Kim6, Eckhard Mayer7, Tomas Pulido8, Chen Wang9, Pablo Colorado10, Arno Fritsch11, Christian Meier12, Sylvia Nikkho12, Marius M Hoeper13. 1. Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France; INSERM Unité 999, l'Hopital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address: gerald.simonneau@abc.ap-hop-paris.fr. 2. Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, Italy. 3. University of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany; German Centre of Lung Research (DZL), Giessen, Germany; Department of Medicine, Imperial College London, London, UK. 4. University of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany; German Centre of Lung Research (DZL), Giessen, Germany. 5. Clinical Department of Cardiology and Angiology of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic. 6. Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA. 7. Kerckhoff Heart and Lung Centre, Bad Nauheim, Germany. 8. National Heart Institute, Cardiopulmonary Department, Mexico City, Mexico. 9. Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Beijing, China; Department of Respiratory Medicine, Capital Medical University, Beijing, China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, China. 10. Global Clinical Development, Bayer Pharma AG, Barcelona, Spain. 11. Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany. 12. Global Clinical Development, Bayer Pharma AG, Berlin, Germany. 13. German Centre of Lung Research (DZL), Giessen, Germany; Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Abstract
BACKGROUND:Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat. We also present safety and efficacy from the final data cutoff of CHEST-2, where most patients had received riociguat for at least 2 years. METHODS:Eligible patients from the CHEST-1 study entered the CHEST-2 open-label extension study, in which all patients received riociguat individually adjusted to a maximum dose of 2·5 mg three times per day. The primary endpoint was safety and tolerability. We did exploratory assessments of associations between markers of disease severity (6-min walking distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO functional class) at baseline and follow-up with overall survival and clinical worsening-free survival. We used Kaplan-Meier and Cox proportional hazards analyses. CHEST-2 is registered at ClinicalTrials.gov, number NCT00910429. FINDINGS:237 patients entered CHEST-2. At 2 years, overall survival was 93% (95% CI 89-96) and clinical worsening-free survival was 82% (77-87). A significant association with overall survival was seen for 6MWD and NT-proBNP concentration at baseline (p=0·0199 and p=0·0183, respectively) and at follow-up (p=0·0385 and p=0·0068, respectively). Change from baseline in 6MWD was also significantly associated with survival (p=0·0047). WHO functional class at baseline and follow-up showed no significant association with overall survival but was associated with clinical worsening-free survival. Riociguat was well tolerated by most patients and no new safety signals were identified. Serious adverse events were seen in 129 (54%) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events. INTERPRETATION: Riociguat may be used long term in patients with CTEPH. 6MWD and NT-proBNP concentration are good prognostic markers. FUNDING: Bayer Pharma AG.
RCT Entities:
BACKGROUND:Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat. We also present safety and efficacy from the final data cutoff of CHEST-2, where most patients had received riociguat for at least 2 years. METHODS: Eligible patients from the CHEST-1 study entered the CHEST-2 open-label extension study, in which all patients received riociguat individually adjusted to a maximum dose of 2·5 mg three times per day. The primary endpoint was safety and tolerability. We did exploratory assessments of associations between markers of disease severity (6-min walking distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO functional class) at baseline and follow-up with overall survival and clinical worsening-free survival. We used Kaplan-Meier and Cox proportional hazards analyses. CHEST-2 is registered at ClinicalTrials.gov, number NCT00910429. FINDINGS: 237 patients entered CHEST-2. At 2 years, overall survival was 93% (95% CI 89-96) and clinical worsening-free survival was 82% (77-87). A significant association with overall survival was seen for 6MWD and NT-proBNP concentration at baseline (p=0·0199 and p=0·0183, respectively) and at follow-up (p=0·0385 and p=0·0068, respectively). Change from baseline in 6MWD was also significantly associated with survival (p=0·0047). WHO functional class at baseline and follow-up showed no significant association with overall survival but was associated with clinical worsening-free survival. Riociguat was well tolerated by most patients and no new safety signals were identified. Serious adverse events were seen in 129 (54%) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events. INTERPRETATION:Riociguat may be used long term in patients with CTEPH. 6MWD and NT-proBNP concentration are good prognostic markers. FUNDING: Bayer Pharma AG.
Authors: Christian Schoenfeld; Jan B Hinrichs; Karen M Olsson; Martin-Alexander Kuettner; Julius Renne; Till Kaireit; Christoph Czerner; Frank Wacker; Marius M Hoeper; Bernhard C Meyer; Jens Vogel-Claussen Journal: Eur Radiol Date: 2018-10-11 Impact factor: 5.315
Authors: Marius M Hoeper; Hossein-Ardeschir Ghofrani; Ekkehard Grünig; Hans Klose; Horst Olschewski; Stephan Rosenkranz Journal: Dtsch Arztebl Int Date: 2017-02-03 Impact factor: 5.594
Authors: F C Roller; S Kriechbaum; A Breithecker; C Liebetrau; M Haas; C Schneider; A Rolf; S Guth; E Mayer; C Hamm; G A Krombach; C B Wiedenroth Journal: Eur Radiol Date: 2018-08-29 Impact factor: 5.315
Authors: Sylwia Sławek-Szmyt; Aleksander Araszkiewicz; Stanisław Jankiewicz; Marek Grygier; Tatiana Mularek-Kubzdela; Maciej Lesiak Journal: J Clin Med Date: 2022-05-12 Impact factor: 4.964
Authors: Vallerie V McLaughlin; Pavel Jansa; Jens E Nielsen-Kudsk; Michael Halank; Gérald Simonneau; Ekkehard Grünig; Silvia Ulrich; Stephan Rosenkranz; Miguel A Gómez Sánchez; Tomás Pulido; Joanna Pepke-Zaba; Joan Albert Barberá; Marius M Hoeper; Jean-Luc Vachiéry; Irene Lang; Francine Carvalho; Christian Meier; Katharina Mueller; Sylvia Nikkho; Andrea M D'Armini Journal: BMC Pulm Med Date: 2017-12-28 Impact factor: 3.317